Moloney Securities Asset Management’s AbCellera Biologics ABCL Stock Holding History

Moloney Securities Asset Management’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$60.4K	Hold	12,000	–	–	0.01%	476
2025 Q2	$41.2K	Sell	12,000 -2,400	-17%	-$5.97K	0.01%	475
2025 Q1	$32.1K	Sell	14,400 -76,000	-84%	-$218K	﹤0.01%	466
2024 Q4	$265K	Buy	+90,400	New	+$252K	0.04%	368
2022 Q3	–	Sell	-15,800	Closed	-$168K	–	380
2022 Q2	$168K	Buy	+15,800	New	+$134K	0.04%	341
2022 Q1	–	Sell	-13,100	Closed	-$187K	–	414
2021 Q4	$187K	Sell	13,100 -9,000	-41%	-$137K	0.03%	411
2021 Q3	$443K	Buy	22,100 +11,200	+103%	+$198K	0.08%	262
2021 Q2	$240K	Sell	10,900 -20,050	-65%	-$553K	0.04%	360
2021 Q1	$1.05M	Buy	+30,950	New	+$1.23M	0.21%	130

Other funds holding ABCL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Moloney Securities Asset Management's ABCL Position: Q3 2025 in Review

Moloney Securities Asset Management held its AbCellera Biologics (ABCL) position steady in Q3 2025 at 12,000 shares worth $60.4K. The position accounts for 0.01% of the portfolio, ranked #476.

Moloney Securities Asset Management first reported a position in ABCL in Q1 2021 and has held it in 9 quarters since. The position peaked at $1.05M in Q1 2021. 141 funds tracked by Wall St. Rank hold ABCL as of Q3 2025.

Moloney Securities Asset Management held 12,000 shares of AbCellera Biologics worth $60.4K as of Q3 2025.
Moloney Securities Asset Management left its AbCellera Biologics share count unchanged in Q3 2025.
AbCellera Biologics made up 0.01% of Moloney Securities Asset Management's portfolio in Q3 2025, its #476 holding.
Moloney Securities Asset Management first reported a position in AbCellera Biologics in Q1 2021 and has held it in 9 quarters since.
Moloney Securities Asset Management's AbCellera Biologics position peaked at $1.05M in Q1 2021.
141 funds tracked by Wall St. Rank held AbCellera Biologics as of Q3 2025.

Based on Moloney Securities Asset Management's 13F filing for Q3 2025, filed 5 Nov 2025.